Q-omics provides the consensus-scored CNGB1 profile across patient tissues and cancer cell-line models. CNGB1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CNGB1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, CNGB1 RNA expression shows 12,705 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where CNGB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNGB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNGB1 survival associations across molecular data types. CNGB1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNGB1 RNA expression–survival associations across cancer types. High CNGB1 expression shows unfavorable associations in KIRC, KIRP, CESC, PAAD, UCEC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CNGB1 RNA expression.
This table summarizes CNGB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CNGB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNGB1 shows lower tumor expression in COAD and KIRC and higher tumor expression in HNSC, THCA, BLCA and LUAD. The HNSC box plot shows higher CNGB1 RNA expression in tumor versus normal tissue (log2 FC = +2.991, t-test p < 0.001).
This table shows molecular features associated with CNGB1 in patient tissues and cancer cell lines. In patient samples, CNGB1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CNGB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
